Paper Details

  1. Home
  2. Paper Details

Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine.

Author: ConleyRobert R, KellyDeanna L, LoveRaymond C, McMahonRobert P, MorrisonJohn A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study examined weight and metabolic changes in patients treated with risperidone and olanzapine, two widely used second-generation antipsychotics. The study addressed the importance of early monitoring for metabolic side effects associated with these medications.
Paper Details　
Original Abstract of the Article :
The second-generation antipsychotics are effective for treating psychotic disorders and incur fewer motor side effects than are commonly experienced with the use of first-generation antipsychotics. However, their use is commonly associated with weight gain and metabolic disturbances. This study exam...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/10401230802017050

データ提供：米国国立医学図書館（NLM）

Metabolic Risk with Second-Generation Antipsychotics

The use of antipsychotics has revolutionized the treatment of psychotic disorders, but they can also have significant metabolic side effects. This research examined the weight and metabolic changes associated with two widely used second-generation antipsychotics, risperidone and olanzapine. The study was a double-blind randomized trial that lasted eight weeks. The researchers found that both antipsychotics were associated with weight gain and metabolic disturbances, highlighting the importance of early monitoring for these side effects.

Navigating the Metabolic Desert

Think of the metabolic consequences of antipsychotics as a vast, unforgiving desert. Weight gain and metabolic disturbances can be like sandstorms, making the journey challenging and potentially dangerous. This research emphasizes the need for careful monitoring and early intervention to mitigate these risks. The study found that both risperidone and olanzapine were associated with metabolic disturbances, suggesting that careful monitoring may be important for all patients taking second-generation antipsychotics.

Mindful Antipsychotic Use: A Guide for Patients and Clinicians

This research provides valuable information for patients and clinicians alike. It underscores the importance of being mindful of the potential metabolic side effects of antipsychotics and of engaging in regular monitoring to identify and address any issues early on. By working together, patients and clinicians can navigate the desert of antipsychotic therapy with greater safety and awareness.

Dr. Camel's Conclusion

This study reveals the delicate balance between the benefits and risks of second-generation antipsychotics. Just as a camel needs to be vigilant in a desert, patients taking these medications should be closely monitored for potential metabolic side effects. By being aware of these risks and collaborating with healthcare professionals, individuals can optimize their treatment and minimize potential complications.
Date :
  1. Date Completed 2008-07-07
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

18568578

DOI: Digital Object Identifier

10.1080/10401230802017050

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.